Therapeutic Management of Hospitalized Adults With COVID-19

**COVID + and Severe disease (SpO\textsubscript{2} < 94% on room air; requiring supplemental O\textsubscript{2})**

**Dexamethasone** 6mg PO or IV daily for 10 days or until off O\textsubscript{2} or discharge

**Remdesivir**
- 200mg IV day 1,
- 100mg IV days 2-5

---

**Deterioration**

**COVID + and Oxygen requirement at >6 LPM O\textsubscript{2} or FiO\textsubscript{2} > 0.5 or mechanical ventilation (IMV)**

**Dexamethasone** 6mg PO or IV daily for 10 days or until off O\textsubscript{2} or discharge

If ≤ 7 days in hospital or nosocomial COVID with ≤ 7 days of symptoms:

- **Tocilizumab**
  - 400mg single dose IV given within 24h of start of IMV
  - or
  - If tocilizumab unavailable: **Baricitinib**
    - 4mg PO daily\textsuperscript{c} x 14 days or until discharge
    - or
    - **Sarilumab**
      - 400mg single dose IV given within 24h of start of IMV

---

**Incidental or Nosocomial COVID with symptoms**
- If ≤ 7 (sotrovimab ≤ 5) days of symptoms and meets outpatient criteria\textsuperscript{a}:
  - **Remdesivir** 200mg IV day 1, 100mg IV days 2-3
  - **Sotrovimab**b 500mg single dose IV

---

**ANTICOAGULATION**: In moderately sick hospitalized COVID-19 patients (requiring oxygen up to 15 L/min via nasal cannula) with no contraindications to anticoagulation and low bleeding risk, therapeutic dose tinzaparin (175 u/kg) is recommended for 14 days or until discharge, to increase the probability of survival until hospital discharge and reduce the need for ICU-level organ support. In critically ill hospitalized COVID-19 patients with no contraindications to anticoagulation, prophylactic dose tinzaparin (75 u/kg) is recommended.
Footnotes

◊ Blue/red arms reflect the need for oxygen or ventilation related to COVID.

a. Outpatient criteria:
   - Immunocompromised, or
   - 0-1 dose of 2-dose vaccine and:
     • Age 55 and over (or age 45 and over if Indigenous), regardless of comorbidities
     • Age 18 and over with at least one of the following comorbidities:
       i. Diabetes requiring medication
       ii. Obesity (BMI > 30 kg/m2)
       iii. Chronic kidney disease (eGFR < 60 mL/min/1.73 m2)
       iv. Congestive heart failure (New York Heart Association class II, III, or IV)
       v. Chronic obstructive pulmonary disease
       vi. Moderate-to-severe asthma
     • Pregnancy

b. Wait 90 days after administration of sotrovimab for COVID vaccination.

c. Adjust baricitinib dose based on eGFR:
   • 30 to < 60 mL/min/1.73 m2: 2 mg PO/NG once daily
   • 15 to < 30 mL/min/1.73 m2: 2 mg PO/NG every other day
   • <15 mL/min/1.73 m2: Use is not recommended.

d. Active highly suspect or proven non-COVID infections and severe underlying immunocompromise are relative contraindications to receipt of tocilizumab, baricitinib, sarilumab. Specialist consultation is suggested in these cases.

If patient meets tocilizumab / baricitinib / sarilumab criteria at presentation, favour one of these agents over remdesivir. If an immunocompetent patient has met criteria for, and been given tocilizumab / baricitinib / sarilumab, the presumption is that they are in a phase of their illness where remdesivir has not been proven beneficial, would not be expected to yield benefit, and should not be used.

Only one of baricitinib / sarilumab / tocilizumab should be used in the same patient; they all work on the same inflammatory pathway, they are unlikely to have added benefit and, and are potent immunosuppressants, so combination use could have adverse effects.